Clinical progress of glucagon-like peptide 1 receptor agonist in
treatment of diabetic nephropathy

doi:10.3760/cma.j.issn.1007-1245.2022.21.033

Abstract

Abstract: Diabetes affects global health problems. Diabetes nephropathy is one of its common microvascular complications, and also one of the major diseases leading to nephropathy (ESRD). At present, glucagon-like peptide 1 receptor agonist (GLP-1RA), one of the hypoglycemic drugs, has become the main treatment for diabetes patients, and can effectively reduce blood glucose. More and more studies have shown that GLP-1RA can protect the kidney no matter what the hypoglycemic effect is. This article analyzes the clinical research progress of GLP-1RA in the treatment of diabetes by analyzing clinical data.

Key words: Glucagon-like peptide 1 receptor, Diabetic nephropathy, Agonist

摘要： 糖尿病影响全球健康问题，糖尿病肾病是其通常的微血管并发症之一，而且还是导致肾病的主要疾病之一（ESRD）。目前降血糖药物中的胰高血糖素-1受体激动剂（glucagon-like peptide 1 receptor agonist，GLP-1RA），成为治疗糖尿病患者的主要方法，能有效降低血糖。越来越多的研究表明，无论低血糖效应如何，GLP-1RA都有保护肾脏的作用。本文通过分析临床资料，分析GLP-1RA应用于治疗糖尿病的临床研究进展。

关键词: 胰高血糖素样肽1受体, 糖尿病肾病, 激动剂

Guo Chaohua, He Qing, Xing Yuanyuan. Clinical progress of glucagon-like peptide 1 receptor agonist in treatment of diabetic nephropathy[J]. International Medicine and Health Guidance News, 2022, 28(21): 3106-3108.

郭超花何晴邢媛媛. 胰高血糖素样肽1受体激动剂治疗糖尿病肾病的临床研究进展[J]. 国际医药卫生导报, 2022, 28(21): 3106-3108.

References

[1] Edelman S, Cassarino D, Kayne D, et al. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist [J]. J Manag Care Spec Pharm, 2022, 28(9): 958-968. DOI: 10.18553/jmcp.2022.28.9.958.
[2] Ginnard OZB, Redondo MJ, Lyons SK. Diabetes of unclear type in an adolescent boy with multiple islet-cell autoantibody positivity successfully managed with glucagon-like peptide-1 receptor agonist alone: a case report [J]. Can J Diabetes, 2022: S1499-2671(22)00215-5. DOI: 10.1016/j.jcjd.2022.07.006.
[3] Feher M, Hinton W, Forbes A, et al. Sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes: protocol for a kidney end points real-world study (COMBi-KID study) [J]. JMIR Res Protoc, 2022, 11(7):e34206. DOI: 10.2196/34206.
[4] Kawada T. Clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: real-world study [J]. Diabetes Metab J, 2022, 46(4): 663-664. DOI: 10.4093/dmj.2022.0131.
[5] 李晨,朱小莹,姜明燕,等.胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白-2抑制剂治疗2型糖尿病疗效及安全性的系统评价[J].中国医院药学杂志,2022,42(16):1697-1702. DOI:10.13286/j.1001-5213.2022.16.13.
[6] 刘燕,袁仁斌,高赟. 胰高血糖素样肽-1受体激动剂治疗2型糖尿病胰腺安全性的Meta分析[J]. 湖南师范大学学报(医学版),2022,19(2):41-44. DOI:10.3969/j.issn. 1673-016X. 2022.02.011.
[7] 张俊清,王紫薇.应用胰高血糖素样肽-1受体激动剂联合口服降糖药血糖控制不佳的2型糖尿病患者转换为iGlarLixi与应用胰高血糖素样肽-1受体激动剂日制剂、周制剂治疗效果的比较:LixiLan-G随机临床试验[J].中国糖尿病杂志,2022,30(4):315-320.
[8] Kim HS, Yoon T, Jung CH, et al. Clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: real-world study [J]. Diabetes Metab J, 2022, 46(4):658-662. DOI: 10.4093/dmj.2021.0232.
[9] 陶娅,王晋竹,王金帆,等. 胰高血糖素样肽-1受体激动剂治疗糖尿病肾病的有效性及安全性分析[J]. 临床和实验医学杂志,2021,20(16):1707-1712. DOI:10.3969/j.issn. 1671-4695.2021.16.008.
[10] 连琯,谢卓霖,李美萱,李勇坤,张定华.基于GRADE系统的胰高血糖素样肽1受体激动剂治疗2型糖尿病的系统评价的再评价[J].中国药房,2020,31(21):2656-2664.
[11] 周亭,汪年松,范瑛.胰高血糖素样肽1受体激动剂治疗糖尿病肾病的临床研究进展[J].世界临床药物,2020,41(10):764-769, 795. DOI:10.13683/j.wph.2020.10.003.
[12] 张春燕,范玲,谢星星.胰高血糖素样肽1受体激动剂治疗2型糖尿病患者疗效的网状Meta分析[J].中国医院药学杂志,2020,40(17):1856-1863. DOI:10.13286/j.1001-5213. 2020.17.13.
[13] 白姜花.胰高血糖素样肽1受体激动剂与二肽基肽酶4抑制剂治疗2型糖尿病的效果比较[J].中国校医,2020,34(4):269-271.
[14] 陈再明. 川芎嗪与胰高血糖素样肽-1受体激动剂治疗2型糖尿病慢性并发症的临床效果[J]. 中国当代医药,2020,27(6):40-42. DOI:10.3969/j.issn.1674-4721.2020.06.011.
[15] 牟永利. 胰高血糖素样肽-1受体激动剂在2型糖尿病治疗中的应用效果[J]. 中国社区医师,2020,36(4):37,39. DOI:10.3969/j.issn.1007-614x.2020.04.018.
[16] Weiss T, Carr RD, Pal S, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States[J]. Patient Prefer Adherence, 2020, 14:2337-2345. DOI: 10.2147/PPA.S277676.
[17] 朱卉,李国娟,范滔,等.胰高血糖素样肽-1受体激动剂治疗2型糖尿病的研究进展[J].湘南学院学报(医学版),2019,21(3):76-79. DOI:10.16500/j.cnki. 1673-498x. 2019. 03.026.
[18] 杨君义. 新型糖尿病治疗药物胰高血糖素样肽1受体激动剂semaglutide[J]. 中国新药杂志,2019,28(7):780-783.
[19] 朱超霞.胰高血糖素样肽-1受体激动剂治疗糖尿病足的疗效和安全性观察[J].慢性病学杂志,2019,20(03):471-472. DOI:10.16440/j.cnki.1674-8166.2019.03.058.
[20] Liu Y, Zhang X, Chai S, et al. Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis [J]. J Diabetes Res, 2019:1534365. DOI: 10.1155/2019/1534365.
[21] 王英俊,罗科学. 胰高血糖素样肽-1受体激动剂治疗2型糖尿病的临床疗效及安全性观察[J]. 中国现代医生,2018,56(36):22-24,28.
[22] 曾玉,王华,赵新兰,等. 胰高血糖素样肽-1受体激动剂治疗糖尿病慢性并发症的研究进展[J]. 中国老年学杂志,2018,38(18):4566-4568. DOI:10.3969/j.issn.1005-9202. 2018.18.076.
[23] 刘心苑,刘尚全. 胰高血糖素样肽1受体激动剂治疗 2型糖尿病的临床进展[J]. 临床荟萃,2018,33(5):446-450,453. DOI:10.3969/j.issn.1004-583X.2018.05.021.
[24] 齐鲁钰,阳柳雪.胰高血糖素样肽-1受体激动剂治疗2型糖尿病的临床疗效及安全性研究进展[J].临床合理用药杂志,2018,11(6):168-170. DOI:10.15887/j.cnki.13-1389/r.2018.06.085.

Clinical progress of glucagon-like peptide 1 receptor agonist in treatment of diabetic nephropathy

胰高血糖素样肽1受体激动剂治疗糖尿病肾病的临床研究进展

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

[1]	Xing Guoqing, Yu Suguo. Research progress of semaglutide in treatment of obesity [J]. International Medicine and Health Guidance News, 2022, 28(7): 898-901.
[2]	Liu Wei, Xu Dandan, Tong Jie, Ren Jianzhi. Effects of different trigger methods on pregnancy outcomes of IVF-ET in patients with polycystic ovary syndrome [J]. International Medicine and Health Guidance News, 2022, 28(7): 933-936.
[3]	Sun Yan, Luo Xiaoqing, Yu Fubing, Lai Wenyao, Lin Qianxia. Efficacy of letrozole co-treatment with antagonist protocol in PORs during in-vitro fertilization treatment [J]. International Medicine and Health Guidance News, 2022, 28(2): 208-211.
[4]	Xue Rumei, Yuan Yuying, Wen Zheling, Sun Hongliang, Zhang Dongmei. In vitro fertilization embryo transfer outcomes of two ovulation induction schemes for patients with diminished ovarian reserve [J]. International Medicine and Health Guidance News, 2022, 28(19): 2744-2748.
[5]	Yao Hongyan. Pharmacokinetic properties of new oral anticoagulants and their clinical application cases [J]. International Medicine and Health Guidance News, 2022, 28(19): 2809-2812.